Waters Corporation and The University of Delaware in the US have announced the grand opening of Immerse Delaware, a new Waters innovation and research laboratory.

As part of their multi-year research partnership announced in October 2021, the lab opening is the first step on a journey to collaborate with biopharma scientists both in industry and academia to advance industrial processes for making and characterizing biotherapeutics.

Located at the University of Delaware Science, Technology and Advanced Research (STAR) campus, Immerse Delaware is a fully functional, fit-for-purpose, bioprocess laboratory enabling a dedicated focus on the entire manufacturing process from clone selection to quality control (QC) of drug substances.

It will give students, faculty and industry researchers access to use and evaluate state-of-the-art analytical technologies from Waters as well as novel analytics, consumables and software that will enable the next generation of biotherapeutics.

“Our mission to address some of the biggest challenges in the development and manufacturing of biotherapeutics requires an immense amount of work, collaboration, and diversity of thought. Immerse Delaware will enable us to tap into an ecosystem of talent and expertise in biological manufacturing, coupled with Waters’ experience in analytical technologies, to advance and accelerate the delivery of high-quality medicines to patients,” said Dr. Udit Batra, President and CEO of Waters Corporation.